Polizzotto, Mark N.

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

Polizzotto, M. N., Uldrick, T. S., Wang, V., Aleman, K., Wyvill, K. M., Marshall, V., Pittaluga, S., O’Mahony, D., Whitby, D., Tosato, G., et al. (2013) · Blood

Viral-associated cancers and disordersLymphadenopathy Diagnosis and Analysis

Cited by 158

Kaposi Sarcoma–Associated Herpesvirus-Associated Malignancies: Epidemiology, Pathogenesis, and Advances in Treatment

Bhutani, M., Polizzotto, M. N., Uldrick, T. S., & Yarchoan, R. (2015) · Seminars in Oncology

Viral-associated cancers and disordersHerpesvirus Infections and Treatments

Cited by 155

Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study

Polizzotto, M. N., Uldrick, T. S., Wyvill, K. M., Aleman, K., Peer, C. J., Bevans, M., Sereti, I., Maldarelli, F., Whitby, D., Marshall, V., et al. (2016) · Journal of Clinical Oncology

Viral-associated cancers and disordersLymphoma Diagnosis and Treatment

Cited by 138

HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults

Dharan, N. J., Yeh, P., Bloch, M., Yeung, M. M., Baker, D., Guinto, J., Roth, N., Ftouni, S., Ognenovska, K., Smith, D., et al. (2021) · Nature Medicine

Acute Myeloid Leukemia ResearchHIV-related health complications and treatments

Cited by 108

Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial

Matthews, G., Jacoby, S., Borok, M., Eriobu, N., Kaplan, R., Kumarasamy, N., Bennet, J. A., Avihingsanon, A., Chetchotisakd, P., Wagner Cardoso, S., et al. (2024) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 31